NECLIFENSENECTAR LIFESCIENCES LTD.· PharmaceuticalsMinimalNeutral
Announced Fri, 18 Sept · 17:07 IST

AGM 2026 voting results: all 5 resolutions passed

NECLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
1-day move
₹11.00
prior close
₹10.99
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+1.3+1.3+1.5
Up moveDown movePending
AI summary

Nectar Lifesciences 31st AGM held on Sept 18, 2026. All 5 resolutions passed: adoption of FY26 standalone and consolidated financial statements, re-appointment of Sanjiv Goyal (MD, retires by rotation), re-appointment of two independent directors Dr Kuldip Bhasin and Dr Indu Pal Kaur for a second 5-year term each, and appointment of Dr Gunmala Suri as Non-Executive Non-Independent Director. About 52.33% of shares voted, with each resolution getting around 99.97% support. Public non-institutions split close to 47/53 on resolutions 2 to 5.

Likely market impact

Routine AGM procedural filing. Board remains largely stable with one new director. No material impact on stock expected.